Trial · NCT03447262
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | VX-659/TEZ/IVA TC | Participants With AEs | 470 | participants | |
| Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | VX-659/TEZ/IVA TC | Participants With SAEs | 99 | participants | |
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | Placebo - VX-659/TEZ/IVA | 14.2 | Standard Deviation 7.8 | percentage points |
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 10.3 | Standard Deviation 9.3 | percentage points |
| Absolute Change in ppFEV1 for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | TEZ/IVA - VX-659/TEZ/IVA | 15.1 | Standard Deviation 11.9 | percentage points |
| Absolute Change in ppFEV1 for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 11.5 | Standard Deviation 9.8 | percentage points |
| Absolute Change in Sweat Chloride (SwCl) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | Placebo - VX-659/TEZ/IVA | -48.9 | Standard Deviation 20.4 | millimole per liter (mmol/L) |
| Absolute Change in Sweat Chloride (SwCl) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | -49.7 | Standard Deviation 20.1 | millimole per liter (mmol/L) |
| Absolute Change in SwCl for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | TEZ/IVA - VX-659/TEZ/IVA | -45.7 | Standard Deviation 16.8 | mmol/L |
| Absolute Change in SwCl for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | -53.5 | Standard Deviation 16.2 | mmol/L |
| Number of Pulmonary Exacerbations (PEx) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | Placebo - VX-659/TEZ/IVA | 60 | PEx events | |
| Number of Pulmonary Exacerbations (PEx) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 84 | PEx events | |
| Number of PEx for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | 39 | PEx events | ||
| Number of Participants With at Least One PEx for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | Placebo - VX-659/TEZ/IVA | 43 | participants | |
| Number of Participants With at Least One PEx for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 52 | participants | |
| Number of Participants With at Least One PEx for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | 28 | participants | ||
| Absolute Change in Body Mass Index (BMI) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | Placebo - VX-659/TEZ/IVA | 1.55 | Standard Deviation 1.35 | kilogram per meter square (kg/m^2) |
| Absolute Change in Body Mass Index (BMI) for Participants From the Parent Study 659-102 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 1.43 | Standard Deviation 1.94 | kilogram per meter square (kg/m^2) |
| Absolute Change in BMI for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | TEZ/IVA - VX-659/TEZ/IVA | 1.16 | Standard Deviation 1.68 | kg/m^2 |
| Absolute Change in BMI for Participants From the Parent Study 659-103 | VX-659/TEZ/IVA TC | VX-659/TEZ/IVA - VX-659/TEZ/IVA | 0.90 | Standard Deviation 1.52 | kg/m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03447262/results